US 11,712,460 B2
Methods of treating chronic disorders with complement inhibitors
Cedric Francois, Prospect, KY (US); and Pascal Deschatelets, West Newton, MA (US)
Assigned to Apellis Pharmaceuticals, Inc., Waltham, MA (US)
Filed by Apellis Pharmaceuticals, Inc., Waltham, MA (US)
Filed on Apr. 20, 2021, as Appl. No. 17/235,281.
Application 17/235,281 is a division of application No. 16/714,252, filed on Dec. 13, 2019, granted, now 11,013,782.
Application 16/714,252 is a division of application No. 16/023,383, filed on Jun. 29, 2018, abandoned.
Application 16/023,383 is a division of application No. 14/128,447, granted, now 10,039,802, issued on Aug. 7, 2018, previously published as PCT/US2012/043845, filed on Jun. 22, 2012.
Claims priority of provisional application 61/499,895, filed on Jun. 22, 2011.
Prior Publication US 2022/0040254 A1, Feb. 10, 2022
Int. Cl. A61K 31/7088 (2006.01); A61K 31/7105 (2006.01); A61K 38/48 (2006.01); A61K 38/12 (2006.01); A61K 38/10 (2006.01); A61B 5/145 (2006.01); G01N 33/68 (2006.01); A61K 39/395 (2006.01); A61B 5/00 (2006.01)
CPC A61K 38/12 (2013.01) [A61B 5/14546 (2013.01); A61B 5/414 (2013.01); A61K 31/7088 (2013.01); A61K 31/7105 (2013.01); A61K 38/10 (2013.01); A61K 38/48 (2013.01); A61K 39/3955 (2013.01); G01N 33/6869 (2013.01); G01N 33/6884 (2013.01); G01N 2800/12 (2013.01); G01N 2800/122 (2013.01); G01N 2800/14 (2013.01); G01N 2800/24 (2013.01)] 19 Claims
 
1. A method of treating a subject in need of treatment for a chronic respiratory disorder or other chronic complement-mediated disorder, the method comprising administering multiple doses of a complement inhibitor to the subject by an intravenous, intramuscular, subcutaneous, or respiratory route according to a dosing schedule in which successive doses are administered on average (i) at least 3 weeks after the plasma concentration of the complement inhibitor decreases to no more than 10% of the maximum plasma concentration that was reached after the previous dose; (ii) at intervals such that the subject's complement activation capacity is at least 50% of baseline for on average at least 3 weeks between doses; or (iii) at intervals at least equal to 10 times the terminal plasma half-life of the complement inhibitor when administered by the same route; and
wherein the complement inhibitor comprises a nucleic acid.